Quelling of Excitotoxicity in Acute Stroke With Ketamine

PHASE2/PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

120

Participants

Timeline

Start Date

July 1, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions

Acute Ischemic Stroke

Interventions

DRUG

Ketamine

IV infusion

OTHER

Normal Saline

IV infusion

DRUG

Midazolam injection

Injection

Trial Locations (1)

Lankenau Medical Center, Wynnewood

All Listed Sponsors

lead

Lower Merion Neurology Research Foundation

OTHER

NCT03223220 - Quelling of Excitotoxicity in Acute Stroke With Ketamine | Biotech Hunter | Biotech Hunter